In Brief: Penederm
This article was originally published in The Rose Sheet
Penederm: Foster City, CA-based firm posts third quarter revenues of $802,000, down 24.1% from the same period a year ago. The company reported a net loss of $1.7 mil. compared to a 1994 third quarter loss of $1.3 mil. According to the firm, the loss "reflect[s] expenses associated with two large human clinical trials...designed to strengthen marketing claims" for the firm's retinoic acid acne products and its KP363 antifungal cream treatments. Penederm has been addressing outstanding clinical issues concerning the retinoic acid products since receiving an "unapprovable" letter for its NDAs from FDA this spring ("The Rose Sheet" Aug. 28, In Brief). During the third quarter, the firm filed marketing approval applications for the acne products in the European Union...
You may also be interested in...
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle
The National Advertising Division concludes that by claiming the Schick Intuition Plus razor "lathers, shaves and moisturizes in one easy step," Energizer Personal Care is implying a long-term post-shave benefit comparable to that awarded by leave-on moisturizer, which is not supported by the company's evidence